TO THE EDITOR
We retrospectively analyzed a cohort of 435 patients who -from 1992 to 1998 -received high-dose chemotherapy and autologous blood cell transplantation for a variety of nonleukemic malignancies at a single institution. Autologous cells and progenitors were mobilized in the blood, with daily administration of rhG-CSF (Filgrastim, Amgen, Thousand Oaks, CA, USA): 600 mg per day SQ, or after administration of various chemotherapy regimens, followed by the daily administration of rhG-CSF, 300 mg per day SQ, starting on day 6, as per institutional protocols. Patients were collected by apheresis: two blood masses were treated, using a Cobe Spectra (Gambro BCT) automated processor; autologous grafts were characterized for their content in CD34 + cells, using murine monoclonal antibodies directed to the CD34 and CD45 antigens, and flow cytometry, according to institutional protocols.
In this cohort of patients, 130 individuals were identified as 'poor mobilizers' because less than 3 Â 10 6 CD34 + cells/kg were collected during the first attempt at mobilization and collection (three aphereses). As expected, patients were older in the 'poor-mobilizer' group than in the 'good-mobilizer' group: 47.5 years vs 44 years , P ¼ 0.007; more patients had multiple myeloma or Hodgkin's disease in the 'poor-mobilizer' group (12 and 35 % vs 9 and 20%, respectively, Po0.001); more patients had bone marrow involvement in the 'poor-mobilizer' group (49 vs 34%, P ¼ 0.003). On average, patients in the 'poor-mobilizer' group also had received higher numbers of chemotherapy treatments before undergoing mobilization and collection: 7 [3-22] vs 6 [2-30], P ¼ 0.01. The proportion of patients mobilized with rhG-CSF alone was higher in the 'poor-mobilizer' group: 83 vs 49%, Po0.001.
Eventually, a proportion of 'poor mobilizers' underwent successive attempts at collection: 83 out of 130 individuals were submitted to a second, and potentially a third attempt at mobilization and aphereses, based on the decision of the referring physician. Out of these 83 patients, 59 (71.1%) eventually reached the threshold value of 3 Â 10 6 CD34 + cells/kg for the cumulative number of collected blood progenitors. Analysis of patient characteristics shows that these 59 subjects differ from the 47 patients for whom a second attempt at mobilization/collection was not performed: they are older (52 years vs 43 years, P ¼ 0.003), include more men (66 vs 38%, P ¼ 0.004), have a different distribution of diagnoses, including more multiple myeloma (51 vs 13%, Po0.001), and include more patients with progressive diseases 24 vs 11%, P ¼ 0.04); all these 'unfavorable' factors may explain the willingness of transplant physicians to proceed with additional cycles of mobilization/ aphereses, in order to obtain higher numbers of autologous progenitors, and perform autologous transplantation in safer conditions. A total of 24 patients experienced successive failures (ie the cumulative number of collected blood CD34 + cells did not reach 3 Â 10 6 CD34 + cells/kg), and nevertheless underwent highdose chemotherapy and auto-logous transplantation: the economics for this subset are analyzed separately, as these individuals cumulated high costs, both for the collection phase and for the transplantation phase of the treatment.
Clinical efficacy, as well as cost-effectiveness were evaluated for patients who were eventually reinfused with less than 3 Â 10 6 CD34 + cells/kg obtained in a single attempt at collection (n ¼ 47), and for patients who were eventually re-infused with more than 3 Â 10 6 CD34 + cells/kg, following more than one attempt at collection (n ¼ 59). Engraftment (and effectiveness) was evaluated as the first of two consecutive days during which the ANC rose above 0.5 Â 10 9 /l for neutrophils, and above 25 Â 10 9 /l for platelets. Direct medical costs were evaluated for each step of the procedure: mobilization, collection, cryopreservation, reinfusion, and immediate follow-up, from admission to discharge. Costs were measured in physical quantities, obtained from detailed observation of each patient medical records: number of mobilizations, number of leukaphereses, quantity of administered rhG-CSF, length of hospital stay, length of IV antibiotic administration, number of transfusions, conditioning regimen, and daily laboratory tests. Monetary values were attributed to each of these quantities on the basis of specific unit costs. A 1999 per diem room cost was computed and used for calculation, using a previously described methodology.
1 rhG-CSF and antibiotics unit costs were the purchasing prices for the hospital. Transfusion unit costs were the official 1999 French prices (established each year through direct government regulations). Laboratory tests were evaluated using the prices of medical technical acts from the national nomenclature that is established and revised by the French public health-care provider ('Sécurité Sociale'). Collection and cryopreservation costs were assessed in 1999 French francs on the basis of a previous study. 2 There is a clinical benefit with a reduced time to platelet recovery, when one achieves collection of more than 3 Â 10 6 CDC34 + cells during repeated attempts at mobilization/collection. Analysis of engraftment demonstrated no dose effect for neutrophil recovery, but showed the existence of a dose effect for platelet recovery: the 'poor mobilizers' who ultimately received more than 3 Â 10 6 CD34 + cells/kg did recover platelets significantly earlier than patients who received less than 3 Â 10 6 CD34 + cells/kg, with a difference of 4 days (14 days [13-15] vs 18 days [12-24], Po0.001), while the difference for neutrophils was only 1 day (12 days [12-14] vs 13 days [12-14], P40.05); these observations cannot be explained by the use of post-transplant rhG-CSF, as a similar proportion of approximately 40% of the patients were administered this hematopoietic growth factor in vivo in both groups.
Computation of costs for these patients demonstrated that additional costs associated with repeated attempts at mobilization/ collection were compensated by a decreased use of health-care resources during the high-dose chemotherapy with autologous blood cell transplantation phase of the procedure (Table 1) ; this is mostly because of a reduced number of platelet and RBC transfusions. Overall, the cost of the entire procedure appears to be similar for both groups. Taking into account the accelerated platelet recovery, it thus appears that this strategy is cost efficient.
We conclude that repeating attempts for mobilization and collection is legitimate in 'poor-mobilizer' patients who are candidates for high-dose chemotherapy and autologous transplantation. Support of high-dose chemotherapy with the reinfusion of Received 13 September 2002; accepted 22 November 2002 autologous blood cells and progenitors is now routinely used for patients with advanced or poor-prognosis malignancies, including lymphoid malignancies and various types of carcinomas. 3 The relation between numbers of collected (infused) cell and progenitor doses, usually assessed as the number of CD34 + cells/kg of body weight, and hematopoietic recovery has been established by many investigators, 4 and bears several important implications, both medical and economical. 1, 5 Different strategies have been designed to obtain high numbers of cells and progenitors, including careful selection of candidate patients, optimization of mobilization regimens, optimization of collection procedures (extended or repeated aphereses), or attempts at expanding part or all of the autologous graft during culture with cytokine combinations. 6 The existence of a 'recommended minimal number' of CD34 + cells/kg of recipient weight -usually evaluated between 2 and 5 Â 10 6 CD34 + cells/kgis now widely accepted, and used to make daily decisions for patients who undergo CD34 + cell monitoring in their peripheral blood and aphereses. While clinical and economical benefits associated with the collection of higher doses of CD34 + cells have been evaluated in a number of studies, 4,7,8 none of these focused attention on 'poor mobilizers', and searched for guidelines on how to manage this situation. In addition, none of these studies includes a complete economical assessment of the entire procedure (mobilization, collection, and transplantation), and provides economic criteria to optimize the collection strategy. Our economic evaluation measures the total cost of the mobilization, collection, and transplant procedure, on a group of individuals who failed to mobilize adequately progenitors in the peripheral blood. Previously published studies offset the cost of the mobilization procedure, 8 or inversely focused only on this specific cost. All costs have to be computed together, as we show that the increase in collection costs may be partially or totally compensated by a decrease in post-transplant costs. This is especially important in view of the development of outpatient post-transplant management programs that lead to a significant decrease in post-transplant costs, increasing the relative weight of the mobilization and collection steps in the entire procedure. Obviously, a retrospective analysis of a cohort of patients who were not included in a unique clinical trial introduces bias in the analysis. However, it more realistically reflects the daily clinical practice of high-dose chemotherapy with stem cell support, including a realistic evaluation of economic parameters. A limitation of our analysis is the choice of the hematological recovery as the effectiveness criteria. More studies are needed to assess the impact of CD34 + cell dose on nonhematopoietic endpoints, including survival and quality of life. Finally, while we provide evidence that 'poor mobilizers' may benefit from repeated attempts at mobilization -collection, the small subset of really 'hard to mobilize' patients (those not achieving 3 Â 10 6 /kg CD34 + cells, despite several attempts at mobilization) deserves further investigation. For these individuals, aphereses and marrow collections can be considered as alternative sources of progenitors for transplantation. They also represent an incentive to develop and evaluate alternative technologies to produce ex vivo large quantities of cells and progenitors for clinical use. Table 1 Costs for mobilization/collection and for high-dose chemotherapy/autologous transplantation, for patients obtaining o3 Â 10 6 /kg CD34+ in one attempt and more or less than 3 Â 10 6 /kg in more than one attempt. TO THE EDITOR Double minutes (dmin) consist of circular acentric chromatin and are a cytogenetic manifestation of gene amplification, presumably providing the cell with a large number of copies of the target oncogene and resulting in growth advantage. They have been reported in a wide variety of neoplastic disorders, being particularly common in neuroblastomas and brain tumors. 1 In hematologic malignancies, however, dmin are found in less than 1% of larger series of acute myeloid leukemias (AML), myelodysplastic syndromes (MDS), chronic myeloproliferative disorders, chronic myeloid leukemias, and acute lymphoblastic leukemias. 1 In these diseases, dmin appear to be more frequent in myeloid malignancies, especially AML, 1 and may be associated with a poor prognosis.
2,3
Most cases display additional chromosomal aberrations; the few cases reported to date with dmin as a sole abnormality have, with one exception, all been AML. 1 Molecular genetic investigations of dmin in hematologic malignancies have revealed that the vast majority contains amplified sequences derived from chromosome band 8q24, including the MYC oncogene, but dmin harboring MLL have also been reported as well as some with amplification of none of these genes. It has been suggested that the amplification of MYC in hematologic disorders with dmin results in an overexpression of this gene and that this would be the pathogenetically important outcome of the aberration. 2, 3 However, an expression analysis of MYC in dmin has only been performed on the leukemic cell line HL60; 4 no such studies of primary hematologic malignancies have been reported to date.
We here describe a chronic myelomonocytic leukemia (CMML) with dmin as the sole chromosomal aberration. In addition, we show, by fluorescence in situ hybridization (FISH) and Northern blot analyses, that MYC is amplified but not overexpressed, strongly suggesting that it is not the target gene.
A 77-year-old woman with atrial fibrillation, hypertension, and hypothyroidism was admitted to the hospital in December 2000 because of increasing fatigue. She had no previous history of malignancy or iatrogenic genotoxic exposure. At admission, the peripheral blood values were as follows: hemoglobin 93 g/l, platelets 100 Â 10 9 /l, and white blood cells (WBC) 60 Â 10 9 /l with monocytosis. The physical examination was unremarkable; there was no hepatosplenomegaly. Microscopy of a blood film showed massive neutrophilia with hypogranulation, occasional metamyelocytes and myelocytes, monocytosis (4.8 Â 10 9 /l), and nucleated erythrocytes (8/200 WBC). The bone marrow smears were hypercellular with expanded granulocytopoiesis. The myeloblast count was normal. Dysplastic features were limited to neutrophilic hypogranulation and the finding of a few megakaryocytes with multiple separate nuclei. A diagnosis of CMML of the myeloproliferative type was made. She was initially treated with hydroxyurea, later supplemented with cytosine arabinoside because of increasing proliferation. However, the patient's condition deteriorated gradually, and she succumbed to the disease in August 2001, 8 months after the diagnosis.
The karyotype by G-banding analysis was 46,XX,8-40dmin[12]/ 46,XX[13] at diagnosis, and no additional aberrations were detected with multicolor-FISH using whole chromosome painting (wcp) probes for combined binary ratio labeling-FISH.
5 FISH using a probe specific for MYC (Vysis Inc., USA) showed that this gene was present in all dmin, as well as in its normal locus at 8q24 (Figure 1 ). However, a Northern blot analysis revealed that although MYC was slightly more expressed than in a normal bone marrow, the level of expression was markedly lower than in a CMML without dmin or trisomy 8 and than in two cell lines (Figure 2) , indicating that the amplification had not caused overexpression of this gene.
Dmin as a sole chromosomal aberration is a rare finding in hematologic malignancies; only 13 cases have been reported to date, and of these, 12 were AML, mainly M2 variants in elderly patients. 1 It is noteworthy that the single non-AML described with dmin as an isolated change was a CMML. 6 The present case is thus the second CMML with dmin as the only chromosomal abnormality. The rapid clinical deterioration of our patient, who died after 8 months, agrees well with several previous reports stating that dmin in general, as well as MYC-containing dmin, is associated with a short survival. 2 However, this has been questioned recently by Bruckert et al, 3 who, in a review of 11 AML with dmin harboring MYC, concluded that dmin may not confer a poor prognosis unless associated with a complex karyotype. In line with this, the CMML patient reported by Sambani et al 6 survived more than 20 months. Furthermore, reviewing the 12 AML with dmin as a sole change 1 revealed survival times of more than 1 year in 7 of the 10 informative cases. Considering that the median age of these 10 AML patients was 73 years (range 64-79), dmin as the single abnormality cannot be claimed to be a poor prognostic sign.
In the present case, the FISH investigation with a probe covering MYC revealed signals for this gene in all dmin, as well as in its normal locus at 8q24 (Figure 1) . Surprisingly, the Northern blot analysis disclosed that MYC was less expressed than in the CMML without dmin (Figure 2 ). This finding strongly suggests that MYC is Received 30 September 2002; accepted 7 November 2002
